Pfizer Inc. (NYSE: PFE) today shared results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), is maintai
NEW YORK, January 18, 2022 - Pfizer Inc. (NYSE: PFE) today shared results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron. Taken together, these in vitro studies suggest that PAXLOVID has the potential to maintain plasma concentrations many-fold times higher than the amount required to prevent Omicron from replicating in cells. “We specifically designed PAXLOVID to retain its activity across coronaviruses, as well as current variants of concern with predominantly spike protein mutations. Following the clinical findings – showing PAXLOVID reduced risk of hospitalization or death by nearly 90% compared to placebo for high-risk patients when treated within five days of symptom onset – we are encouraged by these initial laboratory findings,”
Pfizer s Paxlovid showed an ability to prevent hospitalization and death from the Omicron Covid variant in three lab studies. The drug has been lauded as the best Covid treatment available.
Aquinnah Friday, Dec. 10, and Saturday, Dec. 11 Aquinnah Artisans Holiday Fair 10 am to 4 pm, Aquinnah Town Hall Shop for a wide variety of gift items created by Island artisans, and have fun at the craft table making ornaments and cards. Food will be available from Goldies Food Truck and Orange Peel Bakery. […]